HER2 directed therapy for gastric/esophageal cancers.

Item

http://www.wikidata.org/entity/Q38210387

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

HER2 directed therapy for gastric/esophageal cancers.

@en

type

Item

label

HER2 directed therapy for gastric/esophageal cancers.

@en

prefLabel

HER2 directed therapy for gastric/esophageal cancers.

@en

P1476

HER2 directed therapy for gastric/esophageal cancers.

@en

P2093

David H Ilson

http://www.w3.org/2001/XMLSchema#string

Elizabeth Won

http://www.w3.org/2001/XMLSchema#string

Yelena J Janjigian

http://www.w3.org/2001/XMLSchema#string

P2860

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

HER2 testing in gastric cancer: a practical approach

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

P2888

s11864-014-0292-6

P304

395-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-014-0292-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1031079316

http://www.w3.org/2001/XMLSchema#string

P698

24811128

http://www.w3.org/2001/XMLSchema#string